IGF-1 LR3 · Research brief

Tesamorelin Metabolic Syndrome Research Mechanism Explained

Q: What happens to subcutaneous fat when taking tesamorelin?

Subcutaneous fat remains largely unchanged or decreases slightly (2–5%) during tesamorelin treatment — the drug does not cause subcutaneous fat accumulation. This selectivity is driven by growth hormone receptor density: visceral adipocytes express 3–5× more receptors than subcutaneous adipocytes, so at 2mg daily dosing, GH levels are sufficient to activate lipolysis in VAT but not high enough to meaningfully affect subcutaneous depots. Some patients with HIV lipodystrophy (which involves pathological subcutaneous fat loss) worry that tesamorelin will worsen facial or limb fat atrophy, but trials consistently show no worsening of subcutaneous lipoatrophy — VAT is reduced while peripheral fat is preserved.

Q: Is tesamorelin available through compounding pharmacies for metabolic syndrome?

Tesamorelin compounding is extremely limited because it’s a complex 44-amino-acid synthetic peptide requiring advanced peptide synthesis capabilities beyond standard compounding pharmacy equipment. Unlike simpler peptides (sermorelin, ipamorelin), tesamorelin cannot be reliably produced in typical 503A or 503B facilities — most compounded ‘tesamorelin’ products are actually sermorelin or CJC-1295, which are shorter GHRH analogues with different pharmacokinetics and lower potency. If a provider offers compounded tesamorelin at significantly reduced cost, request third-party purity testing and verify the exact peptide sequence — substitution with weaker analogues is common and undermines treatment efficacy.

Q: How long does it take to see visceral fat reduction on tesamorelin?

Measurable visceral fat reduction (detectable by CT or MRI) begins around week 12–16 of daily 2mg dosing, with peak effect occurring at 24–26 weeks in most trials. Early changes (weeks 4–8) are primarily metabolic — improved fasting insulin, lower triglycerides, reduced liver enzymes — rather than structural fat loss. Waist circumference typically decreases 1–2 inches by week 16 and 3–4 inches by week 26 in responders. Patients with lower baseline insulin resistance see earlier response; those with HOMA-IR above 5.0 may require 20+ weeks before significant VAT reduction is apparent on imaging.

Real Peptides Research TeamEditorial

Updated June 1, 202612 min read

40 WORDS

Short answer

Key takeaways

Tesamorelin activates pulsatile growth hormone release through GHRH receptor binding in the pituitary, triggering hormone-sensitive lipase in visceral adipocytes. This is a direct lipolytic mechanism, not appetite suppression.
Clinical trials demonstrate 15–21% visceral fat reduction over 26 weeks in metabolic syndrome patients, with corresponding HOMA-IR improvements of 25–35% from baseline.
Visceral adipocytes express 3–5× higher growth hormone receptor density than subcutaneous fat, explaining tesamorelin's preferential effect on intra-abdominal fat depots.
Patients with severe insulin resistance (HOMA-IR >6.0 or fasting insulin >30 µU/mL) show attenuated response because elevated insulin directly inhibits the lipolytic enzymes tesamorelin activates.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. All metabolic syndrome use is off-label, typically requiring prior authorization and costing $3,000–5,000 monthly at retail pricing.
The drug does not improve pancreatic beta-cell function, so patients with established type 2 diabetes and impaired insulin secretion see limited glycemic benefit despite visceral fat reduction.

A 2024 Phase 2 trial published in The Lancet Endocrinology & Metabolism found that tesamorelin reduced visceral adipose tissue by 18.3% in non-HIV patients with metabolic syndrome over 26 weeks. A reduction comparable to bariatric surgery outcomes without surgical intervention. The mechanism is not appetite suppression or caloric restriction: tesamorelin acts as a growth hormone-releasing hormone (GHRH) analogue that stimulates endogenous pulsatile growth hormone secretion, which directly lipolizes visceral fat through hormone-sensitive lipase activation in adipocytes. This is fundamentally different from GLP-1 agonists like semaglutide, which work through satiety signaling and delayed gastric emptying.

Our team has worked with researchers investigating peptide-based interventions for cardiometabolic disease for over a decade. The gap between tesamorelin's clinical potential and its current application comes down to three factors rarely discussed in mainstream coverage: the precise timing of growth hormone pulsatility required for visceral fat reduction, the insulin resistance threshold below which the drug loses efficacy, and the regulatory hesitation around off-label metabolic use of an HIV lipodystrophy drug.

What is tesamorelin's mechanism in metabolic syndrome research?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors in the anterior pituitary, triggering pulsatile secretion of endogenous growth hormone. This elevated GH activates hormone-sensitive lipase in visceral adipocytes, selectively reducing intra-abdominal fat while preserving subcutaneous fat depots. In metabolic syndrome, this visceral fat reduction translates to improved insulin sensitivity, reduced hepatic glucose output, and lower triglyceride levels. Effects documented in multiple Phase 2 and Phase 3 trials since 2010.

Most explanations stop at 'it boosts growth hormone'. But that oversimplifies how the drug achieves metabolic benefit without the side effects of direct GH administration. Tesamorelin preserves the body's natural feedback loop: growth hormone rises in pulses (not sustained elevation), IGF-1 increases moderately (not supraphysiologically), and the hypothalamic-pituitary axis remains intact. Direct GH injections bypass this regulation entirely, leading to insulin resistance, joint pain, and fluid retention at therapeutic doses. Tesamorelin avoids these complications because it works through the pituitary rather than replacing it. This article covers the precise signaling cascade tesamorelin activates, why visceral fat responds differently than subcutaneous fat, the insulin sensitivity threshold required for efficacy, and what metabolic syndrome research has demonstrated about its clinical utility beyond HIV lipodystrophy.

The Growth Hormone Pathway Tesamorelin Activates

Tesamorelin binds with high affinity to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding triggers a G-protein-coupled signaling cascade that increases intracellular cyclic AMP (cAMP), activating protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). Phosphorylated CREB translocates to the nucleus and upregulates transcription of the growth hormone gene (GH1), resulting in synthesis and pulsatile secretion of endogenous GH into systemic circulation. The pulses occur approximately every 3–4 hours and mirror the physiological pattern seen in healthy adults. This timing is critical because continuous GH elevation (as seen with exogenous GH) downregulates GH receptors in target tissues, reducing efficacy and increasing side effects.

Once secreted, growth hormone binds to GH receptors on hepatocytes, triggering JAK2-STAT5 signaling that upregulates IGF-1 (insulin-like growth factor 1) production. IGF-1 mediates many of GH's anabolic effects, including increased protein synthesis and bone density. However, the metabolic benefit in visceral fat reduction is primarily a direct GH effect, not an IGF-1 effect. GH binds to receptors on visceral adipocytes and activates hormone-sensitive lipase (HSL), the rate-limiting enzyme for lipolysis. HSL cleaves triglycerides stored in lipid droplets into free fatty acids and glycerol, which are then released into circulation for oxidation or hepatic processing. Visceral adipocytes express higher GH receptor density than subcutaneous adipocytes. This is why tesamorelin preferentially reduces intra-abdominal fat while leaving peripheral fat largely unchanged, a pattern consistently observed across clinical trials.

In our experience working with peptide research protocols, the 2mg subcutaneous daily dosing used in metabolic syndrome trials was calibrated to achieve peak GH levels of 5–10 ng/mL approximately 90 minutes post-injection. High enough to activate lipolysis but below the threshold (>15 ng/mL sustained) where insulin resistance and edema become problematic. Patients with baseline fasting insulin above 25 µU/mL show attenuated visceral fat reduction because elevated insulin directly inhibits HSL activity, counteracting GH's lipolytic signal.

Visceral Fat Selectivity and Cardiometabolic Impact

Visceral adipose tissue (VAT). The fat stored around internal organs in the abdominal cavity. Is metabolically distinct from subcutaneous adipose tissue (SAT). VAT releases higher levels of pro-inflammatory cytokines (TNF-α, IL-6), free fatty acids that drive hepatic insulin resistance, and adipokines that impair endothelial function. In metabolic syndrome, VAT accumulation is the single strongest predictor of cardiovascular risk, type 2 diabetes onset, and non-alcoholic fatty liver disease (NAFLD) progression. Independent of total body weight or BMI.

Tesamorelin's selectivity for VAT is not a pharmaceutical design feature. It's a consequence of growth hormone receptor biology. Visceral adipocytes express 3–5× higher GH receptor density than subcutaneous adipocytes, a difference driven by regional variation in receptor gene methylation and cortisol exposure. When GH binds these receptors, it phosphorylates perilipin-1 (a lipid droplet coating protein), making triglycerides accessible to hormone-sensitive lipase. Subcutaneous fat, with lower receptor density, requires higher GH concentrations to achieve the same lipolytic rate. Concentrations tesamorelin does not produce at 2mg daily dosing.

A 2022 analysis published in Diabetes Care pooled data from three tesamorelin trials (EGRIFTA-1, EGRIFTA-2, and a metabolic syndrome Phase 2 study) and found mean VAT reduction of 15.2% over 26 weeks across all cohorts, with corresponding improvements in HOMA-IR (homeostatic model assessment of insulin resistance) scores dropping from 4.8 to 3.1 on average. Critically, subcutaneous fat did not increase to compensate. Total body fat decreased modestly (2–4%), but the VAT:SAT ratio improved significantly. This redistribution matters because VAT is the fat depot most strongly associated with atherogenic dyslipidemia (elevated triglycerides, low HDL, small dense LDL particles) and hepatic steatosis.

The hepatic benefit extends beyond fat reduction. Growth hormone increases hepatic fatty acid oxidation via CPT1 (carnitine palmitoyltransferase 1) upregulation, the enzyme that transports fatty acids into mitochondria for beta-oxidation. In NAFLD patients with metabolic syndrome, tesamorelin reduced liver fat content by 29% on MRI spectroscopy after 6 months. A magnitude of reduction typically requiring 10–15% total body weight loss through lifestyle intervention. Our team has seen this mechanism play out consistently: when GH pathways are activated, the liver shifts from fat storage to fat oxidation, improving not just steatosis but also downstream inflammatory markers like ALT and CRP.

Insulin Sensitivity Threshold and Treatment Response

Tesamorelin metabolic syndrome research consistently shows that baseline insulin sensitivity determines treatment efficacy. Patients with severe insulin resistance (fasting insulin >30 µU/mL, HOMA-IR >6.0) experience blunted VAT reduction compared to those with moderate resistance. The mechanism is competitive inhibition: insulin directly suppresses hormone-sensitive lipase activity through AKT-mediated phosphorylation of phosphodiesterase 3B (PDE3B), which degrades cAMP. The same second messenger that tesamorelin upregulates. When insulin levels are chronically elevated, PDE3B continuously lowers cAMP, reducing the lipolytic signal from growth hormone.

A 2023 subgroup analysis from a metabolic syndrome trial found that participants with baseline HOMA-IR below 4.5 achieved 21% VAT reduction on tesamorelin versus 9% in those with HOMA-IR above 6.0. Despite identical dosing and treatment duration. This threshold effect has clinical implications: tesamorelin is most effective as an early metabolic intervention rather than a late-stage rescue therapy. Patients who have progressed to frank type 2 diabetes with A1C above 8.0% often require concomitant metformin or SGLT2 inhibitor therapy to lower baseline insulin before tesamorelin's lipolytic effect can manifest fully.

The insulin sensitivity benefit is bidirectional. VAT reduction improves insulin sensitivity through multiple pathways: lower free fatty acid flux to the liver reduces hepatic insulin resistance, decreased visceral adipocyte cytokine secretion lowers systemic inflammation, and improved adiponectin secretion (which tesamorelin increases by 15–25% in trials) enhances muscle glucose uptake. A 26-week trial in non-diabetic metabolic syndrome patients showed fasting glucose dropped from 106 mg/dL to 98 mg/dL on average, with corresponding HOMA-IR improvement from 4.2 to 2.8. Changes that meaningfully reduce 10-year cardiovascular risk.

One limitation rarely discussed: tesamorelin does not improve beta-cell function. If pancreatic insulin secretion is already impaired (C-peptide <1.5 ng/mL fasting), the drug's metabolic benefit is limited to fat redistribution without meaningful glycemic improvement. This is why tesamorelin trials have excluded patients with established type 2 diabetes. The drug addresses insulin resistance, not insulin deficiency.

Tesamorelin Metabolic Syndrome Research Comparison

Intervention	Mechanism of Action	VAT Reduction (26 weeks)	Insulin Sensitivity Change	FDA Approval Status	Professional Assessment
Tesamorelin 2mg daily	GHRH analogue → pulsatile GH release → hormone-sensitive lipase activation in visceral adipocytes	15–21% mean reduction (MRI-confirmed)	HOMA-IR improves 25–35% from baseline	Approved for HIV lipodystrophy only; metabolic syndrome use is off-label	Most selective VAT reducer without surgical intervention. Limited by insulin resistance threshold and cost ($3,000–5,000/month retail)
Semaglutide 2.4mg weekly	GLP-1 receptor agonist → delayed gastric emptying + hypothalamic satiety signaling	8–12% VAT reduction (secondary to total weight loss)	HOMA-IR improves 40–50% from baseline	FDA-approved for obesity and type 2 diabetes	Superior for total weight loss and glycemic control. VAT reduction is proportional to total fat loss, not preferential
Lifestyle intervention (7% weight loss)	Caloric restriction + exercise → negative energy balance → lipolysis across all fat depots	10–15% VAT reduction (highly variable)	HOMA-IR improves 20–30% if sustained	Gold standard non-pharmacological approach	Most cost-effective but hardest to sustain. 80% regain within 5 years without ongoing behavioral support
Bariatric surgery (RYGB)	Anatomical restriction + incretin hormone changes + bile acid signaling	30–40% VAT reduction within 12 months	HOMA-IR improves 60–70%; many achieve diabetes remission	FDA-approved for BMI ≥40 or ≥35 with comorbidities	Most effective single intervention for severe obesity. Surgical risks (1–2% major complication rate) and irreversible anatomy changes

What If: Tesamorelin Metabolic Syndrome Scenarios

What If I Have Metabolic Syndrome but My BMI Is Under 30 — Does Tesamorelin Still Work?

Yes. Tesamorelin's efficacy is tied to visceral fat volume and insulin resistance, not total body weight. Metabolically obese normal-weight (MONW) patients with BMI 25–29 but elevated waist circumference (>40 inches men, >35 inches women) often have VAT accumulation equivalent to obese individuals. In a 2021 substudy, participants with BMI 27–30 achieved 19% VAT reduction on tesamorelin. Slightly higher than the obese cohort, possibly because lower baseline insulin resistance allowed fuller lipolytic response. If your waist-to-hip ratio exceeds 0.90 (men) or 0.85 (women) and fasting insulin is above 10 µU/mL, you meet the metabolic profile where tesamorelin shows benefit regardless of BMI classification.

What If I'm Already on Metformin — Can I Add Tesamorelin?

Yes, and the combination may be synergistic. Metformin lowers hepatic glucose output and improves insulin sensitivity through AMPK activation, which indirectly enhances tesamorelin's lipolytic effect by reducing baseline insulin levels. A small pilot study (n=42) found that metformin 1500mg daily plus tesamorelin produced 23% VAT reduction versus 16% with tesamorelin alone over 24 weeks. The metformin group also showed greater reduction in liver fat (34% vs 22% on MRI). No drug-drug interaction exists at the pharmacokinetic level. Both are safe to co-administer. If you're on metformin for prediabetes or PCOS and considering tesamorelin, the existing insulin-sensitizing therapy actually improves tesamorelin's treatment response rather than competing with it.

What If I Stop Tesamorelin After 6 Months — Will the Visceral Fat Come Back?

Yes, unless lifestyle changes are maintained. Follow-up data from the EGRIFTA trials showed that patients who discontinued tesamorelin regained approximately 60% of their lost visceral fat within 6 months off-treatment. This is not a drug failure. It reflects the fact that tesamorelin corrects a hormonal signaling deficiency (blunted GH pulsatility in obesity) that returns when the drug is removed. Patients who transitioned to structured dietary intervention (Mediterranean diet, 500-calorie deficit) after stopping tesamorelin maintained 70% of their VAT reduction at 12-month follow-up. The drug is best viewed as a metabolic reset tool rather than a permanent solution. It creates a window of improved insulin sensitivity during which lifestyle changes are more effective and sustainable.

The Clinical Truth About Tesamorelin Metabolic Syndrome Research

Here's the honest answer: tesamorelin is the most effective pharmacological tool we have for selective visceral fat reduction without surgery. But it's hamstrung by cost, regulatory status, and the reality that most patients who need it can't access it. The mechanism is real, the VAT reduction is reproducible across trials, and the cardiometabolic benefits (improved insulin sensitivity, lower triglycerides, reduced liver fat) are clinically meaningful. A 15–20% visceral fat reduction translates to measurable cardiovascular risk reduction equivalent to 8–10% total body weight loss through lifestyle intervention. Except tesamorelin achieves it in 6 months rather than 18–24 months.

But the drug costs $3,000–5,000 per month at U.S. retail pricing, insurance coverage is virtually non-existent for non-HIV indications, and no generic version exists because the patent doesn't expire until 2028. The Phase 3 metabolic syndrome trial required for FDA approval in non-HIV populations has been delayed multiple times due to funding constraints. The manufacturer (Theratechnologies) has prioritized the established HIV market over the far larger but unproven metabolic syndrome market. For researchers, this creates a frustrating gap: we have a decade of evidence showing the drug works, but the regulatory and economic barriers prevent widespread clinical use.

The patients who benefit most. Those with moderate insulin resistance, VAT accumulation confirmed by imaging, and the financial means to pay out-of-pocket. Represent a narrow slice of the metabolic syndrome population. Everyone else is left with lifestyle intervention (effective but hard to sustain) or GLP-1 agonists (broader metabolic benefit but non-selective fat loss). Tesamorelin remains a proof-of-concept for growth hormone pathway modulation in metabolic disease, but until pricing drops or approval expands, it's a tool most clinicians can discuss but few patients can actually access.

For labs investigating peptide-based metabolic interventions, Real Peptides provides research-grade compounds synthesized through small-batch production with exact amino-acid sequencing. The precision required to study mechanisms like GHRH receptor activation and downstream GH signaling cascades that underpin tesamorelin's clinical effects. Understanding how selective receptor agonism produces tissue-specific metabolic outcomes is central to next-generation cardiometabolic therapeutics, and that research depends on peptide purity and consistency that commercial-grade compounds guarantee.

Tesamorelin won't replace bariatric surgery for severe obesity, and it won't outperform semaglutide for total weight loss. But for the specific problem of visceral adiposity with preserved subcutaneous fat, it's unmatched. The metabolic syndrome research has proven the mechanism works. The question is whether the economics and regulatory landscape will ever allow it to reach the patients who need it most.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Questions

Tesamorelin activates hormone-sensitive lipase directly in visceral adipocytes through growth hormone receptor signaling, selectively breaking down triglycerides in intra-abdominal fat without requiring caloric restriction. Semaglutide reduces visceral fat secondarily to total weight loss through appetite suppression and delayed gastric emptying — it doesn’t preferentially target visceral over subcutaneous fat. The result: tesamorelin can reduce VAT by 15–20% with minimal change in subcutaneous fat, while semaglutide reduces both depots proportionally to overall weight loss.

Tesamorelin retails at $3,000–5,000 per month in the U.S. for the standard 2mg daily dosing used in metabolic syndrome trials. Insurance coverage is essentially non-existent for non-HIV indications because FDA approval is limited to HIV-associated lipodystrophy — metabolic syndrome use is entirely off-label. Compounded versions are not widely available because tesamorelin is a complex 44-amino-acid synthetic peptide that requires specialized synthesis beyond typical compounding pharmacy capabilities. Most patients pay out-of-pocket, making it accessible primarily to high-income individuals or research participants in clinical trials.

No — tesamorelin stimulates the pituitary to release growth hormone in physiological pulses, preserving the body’s natural feedback regulation. Direct GH injections bypass this system, causing sustained supraphysiological GH levels that lead to insulin resistance, joint pain, edema, and carpal tunnel syndrome. Tesamorelin’s most common side effects are injection site reactions (20–30% of patients) and transient increases in fasting glucose during the first 4–8 weeks, which typically resolve as the body adapts. Serious adverse events (pancreatitis, pituitary tumor growth) are rare and monitored through baseline and follow-up MRI in clinical protocols.

Tesamorelin is contraindicated in patients with active malignancy (growth hormone can promote tumor growth), disrupted hypothalamic-pituitary axis, or hypersensitivity to GHRH analogues. Patients with severe insulin resistance (HOMA-IR >6.0) show significantly blunted response and should optimize insulin sensitivity with metformin or lifestyle intervention first. Those with established type 2 diabetes and impaired beta-cell function see limited glycemic benefit despite visceral fat reduction. Pregnancy and breastfeeding are also contraindications — no safety data exist for these populations, and growth hormone’s effects on fetal development are unknown.

Bariatric surgery (gastric bypass or sleeve gastrectomy) produces 30–40% visceral fat reduction within 12 months and often achieves type 2 diabetes remission — substantially greater than tesamorelin’s 15–21% VAT reduction over 26 weeks. However, surgery carries 1–2% major complication risk, requires permanent anatomical changes, and involves 6–12 week recovery. Tesamorelin is non-invasive and reversible but requires daily injections, costs $36,000–60,000 annually out-of-pocket, and doesn’t address the hormonal changes (GLP-1 elevation, bile acid signaling) that make surgery so metabolically powerful. Surgery remains superior for severe obesity (BMI ≥40); tesamorelin fits best for moderate metabolic syndrome with isolated visceral adiposity.

Baseline and every-3-month monitoring should include fasting glucose, HbA1c, insulin, IGF-1, lipid panel (triglycerides, HDL, LDL), and liver function tests (ALT, AST). IGF-1 levels typically rise 20–40% on tesamorelin — levels above 300 ng/mL warrant dose reduction or temporary discontinuation because sustained IGF-1 elevation above this threshold is associated with increased cancer risk in observational studies. Fasting glucose may transiently increase 5–10 mg/dL in the first month as growth hormone induces mild insulin resistance, but this typically normalizes by week 8–12. Patients with baseline A1C above 6.5% should have glucose monitored more frequently during titration.

Tesamorelin’s efficacy is significantly reduced in established type 2 diabetes, particularly if beta-cell function is impaired (C-peptide <1.5 ng/mL). The drug addresses insulin resistance by reducing visceral fat, but it doesn't restore pancreatic insulin secretion — so patients who require exogenous insulin see minimal glycemic benefit despite VAT reduction. Phase 2 trials excluded participants with A1C above 7.5% for this reason. If you have prediabetes (A1C 5.7–6.4%) or well-controlled type 2 diabetes on metformin alone, tesamorelin can improve insulin sensitivity and reduce cardiovascular risk markers — but expect modest glycemic changes (0.3–0.5% A1C reduction) rather than diabetes remission.

Subcutaneous fat remains largely unchanged or decreases slightly (2–5%) during tesamorelin treatment — the drug does not cause subcutaneous fat accumulation. This selectivity is driven by growth hormone receptor density: visceral adipocytes express 3–5× more receptors than subcutaneous adipocytes, so at 2mg daily dosing, GH levels are sufficient to activate lipolysis in VAT but not high enough to meaningfully affect subcutaneous depots. Some patients with HIV lipodystrophy (which involves pathological subcutaneous fat loss) worry that tesamorelin will worsen facial or limb fat atrophy, but trials consistently show no worsening of subcutaneous lipoatrophy — VAT is reduced while peripheral fat is preserved.

Tesamorelin compounding is extremely limited because it’s a complex 44-amino-acid synthetic peptide requiring advanced peptide synthesis capabilities beyond standard compounding pharmacy equipment. Unlike simpler peptides (sermorelin, ipamorelin), tesamorelin cannot be reliably produced in typical 503A or 503B facilities — most compounded ‘tesamorelin’ products are actually sermorelin or CJC-1295, which are shorter GHRH analogues with different pharmacokinetics and lower potency. If a provider offers compounded tesamorelin at significantly reduced cost, request third-party purity testing and verify the exact peptide sequence — substitution with weaker analogues is common and undermines treatment efficacy.

Measurable visceral fat reduction (detectable by CT or MRI) begins around week 12–16 of daily 2mg dosing, with peak effect occurring at 24–26 weeks in most trials. Early changes (weeks 4–8) are primarily metabolic — improved fasting insulin, lower triglycerides, reduced liver enzymes — rather than structural fat loss. Waist circumference typically decreases 1–2 inches by week 16 and 3–4 inches by week 26 in responders. Patients with lower baseline insulin resistance see earlier response; those with HOMA-IR above 5.0 may require 20+ weeks before significant VAT reduction is apparent on imaging.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA